Colorectal cancer (CRC) represents one of the most urgent yet addressable oncology challenges confronting Latin America. In Mexico, digestive tract cancers remain a leading contributor to cancer mortality, while CRC continues to rank as the second-most common malignant neoplasm among Latino populations in the Americas.

This crisis stems less from a lack of therapeutic advances than from severe diagnostic bottlenecks. In several large regional hospital networks, the median interval from initial symptom onset to definitive treatment stretches to seven months. The longest portion of that delay occurs between initial clinical evaluation and diagnostic confirmation. When health systems rely on late stage symptomatic presentation, oncology care becomes reactive, expensive, and frequently palliative.

Overall ultra-processed food (UPF) consumption was not associated with increased colorectal cancer (CRC) incidence in a cohort of more than 400,000 U.S. adults, according to a study published October 15^th by Erikka Loftfield of the National Cancer Institute, U.S., and colleagues in the open access journal PLOS Medicine.

An international collaborative research study led by investigators from the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) and the University of California San Diego, has found that exposure to Helicobacter pylori (H. pylori), a bacterium known to cause stomach ulcers and gastric cancer, may be associated with approximately 22% of colorectal cancer cases globally. The findings highlight the potential public health benefits of H. pylori screening and eradication programmes, which would help prevent gastric cancer and reduce the risk of colorectal cancer. The study was published in eGastroenterology.

Researchers at the University of South Florida, Tampa General Hospital and Hokkaido University have uncovered an important mechanism behind immune evasion in metastatic colorectal cancer (mCRC). The finding challenges a 30-year-old theory in cancer research and identifies a molecular pathway that offers a new target for treatment.

CSHL Assistant Professor Semir Beyaz and colleagues have shown that transcription factor PPARD can promote the fitness of both cancer and immune cells. Their research could help make CAR T-cell therapy effective against colorectal cancer and lead to new treatment strategies for endometriosis, among other conditions.

Scientists have developed a simple yet powerful strategy to overcome a long-standing challenge in cancer phototheranostics—the trade-off between imaging brightness, therapeutic efficacy, and biological stability. By systematically replacing hydrogen atoms with deuterium (a heavier isotope) in a near-infrared fluorescent molecule, researchers achieved simultaneous improvements in all three critical properties. The optimized nanoparticles delivered 26% higher fluorescence brightness, 14% more reactive oxygen species for killing cancer cells, and 20% better stability in blood. In mouse models, a single treatment completely eliminated breast tumors, and fluorescence-guided surgery enabled precise removal of colorectal cancer remnants that were invisible under white light—extending survival from under 20 days to over 60 days. The strategy is broadly applicable and does not require redesigning the molecular backbone, offering a versatile platform for next-generation cancer theranostics.

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq^®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).